SOSylviane Olschwang

Sylviane Olschwang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sylviane Olschwang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial.

    by Camille Sibertin-Blanc, Aurelie Fabre, Thomas Aparicio, Karine Le Malicot, Jaafar Bennouna, Francois Ghiringhelli, Julien Taïeb, Valerie Boige, Olivier Bouche, Roger Faroux, et al.

    3534 Background: Bevacizumab (Bev) is widely used in mCRC but there is no validated predictive factor. Several studies have reported the impact of SNPs in the Vascular Endothelial Growth Factor-A (VEGF-A) pathway genes on the Bev’s efficacy but results in the mCRC are yet inconstant. PRODIGE 9 is a phase III trial that compare the tumor control duration (TCD) under a 1st-line chemotherapy followed by either Bev maintenance (Arm A) or no treatment during chemotherapy-free intervals (CFI) (Arm B).The aim of our study was to evaluate the impact of genetic polymorphisms of VEGF A, VEGFR1, VEGFR2 and HIF1α on TCD, duration of 1stCFI, progression-free survival (PFS) and overall survival (OS). Methods: We included patients (pts) of the PRODIGE 9 study for whom biological consent was signed and a DNA sample was available. Ten polymorphisms were genotyped on germ line DNA using real-time Polymerase Chain Reaction. DNA was extracted from blood samples. Survival analyses were done using Kaplan-Meier method and Cox model. For tRR, a logistic regression was used. Results: Among the 491 pts randomized in PRODIGE 9, DNA was available for 314 pts: 160 in Arm A and 154 in Arm B . The median TCD, OS and PFS, were respectively 15.7, 22.6 and 9.2 months (m). For VEGFR-1 rs9582036, pts with CC genotype had significantly better TCD (median [95%CI] 22.4 m [14.7- NR]) compared to pts with AA and CA genotypes (14.4 m [11.7-17.1] (p = 0.04)) in arm A whereas there was no difference in the other arm. This tendency was observed also for the 1st CFI (median 4.6 m for pts CC vs 4.1 m for AC and AA), for the median OS (28.2 vs 22.5 m), the RR, but it was not statistically significant (table). Conclusions: In this prospective study, VEGFR-1 rs9582036 variants were associated with clinical outcome in terms of TCD for patients with mCRC treated by Bev-based therapy. Clinical trial information: NCT00952029.


    • 4 February 2011
      • Vol. 8  (1) , 15-8

    BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.

    by Jinghua Qiu, Marion Compagnone, Sophy Laibe, Arnaud Lagarde, Anthony Goncalves, Olivier Turrini, Luc Xerri, Geneviève Monges, Sylviane Olschwang

    Oncogenic activation of EGF-signalling pathway is central to the progression of colorectal cancer. The use of mutations of the KRAS codons 12 and 13 as a selection biomarker for anti-endothelial growth factor receptor (EGFR) monoclonal antibody treatment is at present the first major step towards individualised treatment for patients with metastatic colorectal cancer. The impact of BRAF V600E mutation is not well documented. A total of 803 metastatic cancer samples from colorectal cancer patients were explored for KRAS exon 2 and BRAF exon 15 mutations. BRAF mutated samples were characterized for mismatch repair function. Overall, 344 tumours were mutated, with 34 of them involving BRAF mutations (8 of microsatellite instability type). No specificity was found according to gender, age at diagnosis and tumour localisation. A complete analysis of KRAS, BRAF and PIK3CA status may identify approximately 10-15% additional patients who are unlikely to respond an EGFR-targeted monoclonal antibody and who may benefit from prospective and specific new biomarker-driven studies.